Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.0%

1 terminated out of 25 trials

Success Rate

93.8%

+7.2% vs benchmark

Late-Stage Pipeline

16%

4 trials in Phase 3/4

Results Transparency

20%

3 of 15 completed with results

Key Signals

3 with results94% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (5)
P 1 (3)
P 2 (8)
P 3 (4)

Trial Status

Completed15
Unknown4
Recruiting2
Withdrawn1
Active Not Recruiting1
Not Yet Recruiting1

Trial Success Rate

93.8%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT06822478Phase 3RecruitingPrimary

Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.

NCT07504757Recruiting

LEISH-PED: Study on Leishmaniasis in Children

NCT06917040Phase 3CompletedPrimary

Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria

NCT05094908Phase 1Active Not RecruitingPrimary

Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis

NCT06695143Phase 3Not Yet RecruitingPrimary

Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia

NCT00508963UnknownPrimary

Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

NCT05708625Phase 3UnknownPrimary

Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis

NCT03969134Phase 2CompletedPrimary

A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL

NCT03999970Not ApplicableCompletedPrimary

A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol

NCT04072874Phase 1WithdrawnPrimary

Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.

NCT03303898Not ApplicableCompletedPrimary

ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -

NCT04888130CompletedPrimary

Investigation of an Outbreak Situation of Cutaneous Leishmaniasis Among Military Personnel in French Guiana (CEFELEISH)

NCT04841239Not ApplicableCompletedPrimary

Development of Topical Herbal Formulations for Treatment of Cutaneous Leishmaniasis

NCT03096457Phase 2CompletedPrimary

Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia

NCT01641796UnknownPrimary

Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis

NCT02894008Phase 2CompletedPrimary

A Study of a New Leishmania Vaccine Candidate ChAd63-KH

NCT01140191Phase 2TerminatedPrimary

Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis

NCT03762070UnknownPrimary

Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru

NCT03445897Phase 2CompletedPrimary

Miltefosine Plus IL Pentamidine for Bolivian CL

NCT03294161Phase 2Completed

Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis

Scroll to load more

Research Network

Activity Timeline